Singapore grants provisional approval for the first bivalent COVID-19 booster vaccine

On Wednesday (September 14), the Health Sciences Authority (HSA) gave interim permission for the first bivalent COVID-19 booster vaccination to be used in the country.

The SARS-CoV-2 original strain and the Omicron BA.1 variant are the ones that are targeted by the two different components of the Spikevax Bivalent Original/Omicron COVID-19 injection that are manufactured by Moderna.

According to a statement made by HSA in a news release, it is an improved version of the Moderna COVID-19 vaccine that is only based on the primary SARS-CoV-2 strain.

Those patients aged 18 years and older who have previously been vaccinated against COVID-19 as part of the primary series are eligible to get it as a booster shot.

The provisional authorization was issued in accordance with the Pandemic Special Access Route in Singapore (PSAR).

According to statements made by Health Minister Ong Ye Kung in front of Parliament on Tuesday, the Ministry of Health has reached agreements with the pharmaceutical companies Pfizer-BioNTech and Moderna to deliver their new bivalent vaccinations into the country.

Keep Reading

Both the ancestral strain of COVID-19 and the Omicron variation, which includes the BA.4 and BA.5 strains, are targeted by the bivalent vaccinations.

The Moderna booster shot is a single dosage that consists of two components: 25 micrograms that target the original strain of SARS-CoV-2, and 25 micrograms that target the Omicron BA.1 variant.

In due time, the Expert Committee on COVID-19 Immunization and the Ministry of Health (MOH) will release official vaccination recommendations utilizing this booster, according to the HSA.

HSA stated that it had carefully examined the data from Moderna’s pre-clinical studies, clinical trials in human volunteers, manufacturing and quality controls, and reached the conclusion that the benefits of using the bivalent vaccine as a booster to protect against COVID-19 outweighed the risks of doing so. This was due to the fact that the virus is continuing to evolve.

In addition, the HSA stated that it engaged with members of its Medicines Advisory Committee and Panel of Infectious Diseases Experts before making its conclusion about the regulatory framework.

The regulatory body stated that its clinical analysis was based on an ongoing Phase 2/3 trial that was carried out by Moderna in people who were at least 18 years old.

Katherine S

1/4 German, 3/4 Malaysian. I write, follow and monitor closely political news happening in Malaysia, and other happening news in the ASEAN region. Newswriter for the best ASEAN news website - The Asian Affairs.

Recent Posts

Vietnam International Defense Expo 2024

The 2024 Vietnam International Defense Expo was inaugurated by the Prime Minister Pham Minh Chinh on December 19, 2024 and…

December 22, 2024

Shooting concludes: Stranger Things 5 to release on Netflix in 2025

Created by the Duffer Brothers, Stranger Things is one of the most popular sci-fi horror series globally. It is set…

December 21, 2024

China’s Hypersonic Expansion in Asia Raises Alarms for India

According to the US Department of Defense, China has now produced the most sophisticated supply of hypersonic weapons in the…

December 21, 2024

Melaka International Halal Festival 2024

The Melaka International Halal Festival 2024 aims to turn the city as the prime center of the Halal products and…

December 21, 2024

Chunichi Dragons Renews the Contract of Hiroto Takahashi with Annual Salary of 120 million yen

On Saturday, the stalwart of Chunichi Dragons Pitcher, Hiroto Takahashi attended the negotiation for his contract renewal for the next…

December 21, 2024

Biden-Harris administration cancels another $4.28 billion in US student loans

US President Joe Biden has cancelled another $4.28 billion in student loans for nearly 55,000 people across the country, the…

December 20, 2024

This website uses cookies.

Read More